CLINICAL RESEARCH INTEGRATES WITH GP AND PHARMACIST WORKFLOWS TO SUPPLEMENT PRACTICE REVENUE Primary health introductions to clinical trials leverages community trust in HCPs
With Charlotte Bradshaw,
CEO and Founder Evrima Technologies
SEGMENT
Filmed in Sydney | January 2025
Clinical trials are crucial to the development of evidence-based preventative medicines. In addition, participation in clinical trials can also provide patients with opportunities to access new treatments.
“Clinical trials are at the heart of medical advances which look into new ways to treat, prevent, or detect disease. Volunteers often do so to help contribute to advancing scientific research, knowing that they are participating in the hope of helping future generations,” said Charlotte Bradshaw, CEO and Founder to Evrima Technologies.
Ms Bradshaw spoke to Australian Health Journal about Evrima’s mission. As an Australian-based digital health company bringing trials to patients, GPs and pharmacists, world-class researchers are able to connect to the wider community through primary health care.
There are hundreds of clinical trials happening around the country and they can take place in hospitals, universities, private clinics and dedicated medical research institutes, yet the trusted role of a GP and pharmacists has opportunity to connect the stakeholder groups.
Research reveals that in Australia, 79% of people would consider being involved in a clinical trial, and 69% would be open to hearing about clinical trials from their GP or Health Care Practitioner. However, barriers such as time constraints, workforce shortages and lack of knowledge about the trials have been identified as barriers to GP referrals.
Each year, clinical trials are conducted to investigate treatment strategies (75%), disease prevention (15%), drugs and medicines (45%), and devices, lifestyles, and behaviours.
In Australia, trials that attract higher participation often centre around cancer and cardiovascular disease. Health conditions such as mental health, neurological and musculoskeletal trials, as well as those dealing with everyday issues including asthma and hypertension, often experience lower rates of participation.
With around 80% of clinical trials being delayed due to recruitment issues, Ms Bradshaw says that new referral platforms such as Evrima’s Evripath can simplify the process for practitioners and patients.
“We understand the daily challenges faced by GPs, but also appreciate that GPs are the gatekeepers to patient participation in clinical trials that are working towards better community outcomes,” said Ms Bradshaw.
Note: Research noted above is cited in the segment
-
Developing the next generation of medicines to target and enhance the microbiome
Australian Health Journal spoke to Associate Professor Sam Forster, Research Group Head
Microbiota and Systems Biology, Hudson Institute of Medical Research, Team Leader, Australian Microbiome Culture Collection & Chief Scientific Officer, BiomeBank and Dr Sam Costello, Co-Founder and CEO of BiomeBank about the microbiome, partnering and some of the breakthroughs in recent years. -
Surgical Site Infection (SSI) Synopsis, including modifiable and non-modifiable risk factors
Talking to the Australian Health Journal, Professor Russo states there is a particular concern in joint operations, such as hip or knee replacements, as infections in these areas can have severe consequences, including the removal of the infected joint, prolonged treatment, and significant costs for both hospitals and patients. Despite the substantial impact of surgical site infections, Australia lacks a national surveillance program for these infections, making it challenging to obtain accurate data. However, an estimate suggests that around 45,000 surgical site infections occur annually in Australia, resulting in approximately 900 deaths.
-
Sharing the same goals in value-based procurement
Value-based procurement (VBP) is a journey, not a sprint. It’s about putting the patient at the centre of quality affordable healthcare through changes in procurement practices for medical technologies. Patient outcomes drive value and sustainability, not just price. The bigger picture indicates that VBP will create system cost saving through benefitting patients, rather than trying to attain the reverse – a win-win outcome.
